MXCT250117C5000
- 0.25
- 0.000.00%
MaxCyte Newsroom
Press Release: MaxCyte Announces Retirement of Board Member Art Mandell
BlackRock Adjusts Stake in MaxCyte, Influencing Voting Rights
MaxCyte Announces Change in Major Shareholdings
MaxCyte's Strategic Growth and Cost Efficiency Drive Buy Rating
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating
MaxCyte (MXCT) Initiated With a Buy at Craig-Hallum
MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance
MaxCyte: Expect Around $5.8M in 2025 Cost Savings From This Action >MXCT
MaxCyte: Made Adjustments to Workforce Affecting Around 15% of Global Personnel >MXCT
MaxCyte Announces Completion of Internal Operational Review >MXCT
Express News | MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
MaxCyte Expands Stock Capital Amid Cell Therapy Growth
MaxCyte Sees Shift in BlackRock's Shareholding
This MaxCyte Insider Increased Their Holding In The Last Year
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
BTIG Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $8
MaxCyte Weighs Delisting From AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $11
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating, Announces Target Price $7
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating